Insilico Medicine, a clinical-stage biotechnology company that uses generative artificial intelligence (AI) to accelerate drug discovery and development, has completed its initial public offering (IPO) on the Hong Kong Stock Exchange (HKEX), marking the largest biotech IPO in Hong Kong in 2025 by funds raised. The company’s shares were priced at HK$24.05, raising about HK$2.277 billion in the offering and achieving a substantial market valuation upon debut. This transaction also established Insilico as one of the first AI-driven biotech firms to list on HKEX’s Main Board under the exchange’s Chapter 8.05 listing rules, signalling strong investor interest in AI-enabled life sciences.
Insilico’s global investor lineup included major pharmaceutical, technology, sovereign fund and asset-management firms—such as Eli Lilly, Tencent, Temasek, Schroders, UBS Asset Management and Oaktree Capital—reflecting broad institutional support for the company’s AI-led drug discovery platform, Pharma.AI. The offering saw oversubscription multiples that highlight robust demand from both public and international institutional investors.
Founded in 2014 with a mission to integrate AI across early-stage drug discovery and development, Insilico uses its proprietary platform to identify targets, generate novel molecules and accelerate candidate advancement into clinical development. By leveraging advanced machine learning, generative chemistry and automated laboratory systems, the company says it can reduce the time and resources required to progress drug candidates compared with traditional discovery approaches.
Proceeds from the IPO are expected to support further clinical research, expansion of generative AI models and laboratory automation, strengthening Insilico’s position at the intersection of AI and biopharmaceutical innovation. The successful listing underscores growing momentum for AI-driven technologies in drug discovery and the life sciences investment landscape.
